Literature DB >> 20486990

Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease.

Johan Lorenzen1, Robert Krämer, Volker Kliem, Stefanie M Bode-Boeger, Hendrik Veldink, Hermann Haller, Danilo Fliser, Jan T Kielstein.   

Abstract

BACKGROUND: The pleiotropic cytokine osteopontin (OPN) is thought to be involved in the pathogenesis of atherosclerosis. However, the relationship between OPN and renal function, a cardiovascular risk factor itself, is not known. Therefore, we assessed the relationship between OPN plasma levels and renal function in patients at different stages of chronic kidney disease (CKD).
METHODS: We studied 49 non-diabetic and non-smoking patients with primary kidney disease at different CKD stages (K/DOQI 1-5). True glomerular filtration rate (GFR) in patients was assessed using the inulin-clearance technique. To examine the role of an abrupt change in GFR on circulating OPN, 15 living related kidney donors were studied before and after unilateral nephrectomy. Twenty matched non-smoking healthy subjects served as controls.
RESULTS: OPN plasma levels in patients with CKD stage 1 (i.e. GFR above 90 mL min(-1) 1.73 m(-2)) were comparable with controls. OPN levels increase in a linear fashion with declining GFR (r = -0.9, P < 0.0001), so that the increase in OPN mirrors the severity of renal impairment. After unilateral nephrectomy, circulating OPN increased significantly in parallel to the decrease in GFR. We found a direct association between OPN and other markers of renal function (serum-creatinine, homocysteine and symmetric dimethylarginine,) as well as with cardiovascular risk factors such as asymmetric dimethylarginine (r = 0.36, P = 0.0213).
CONCLUSION: There is a close inverse association between GFR and circulating OPN in patients with CKD. Furthermore, OPN plasma levels correlate with established cardiovascular risk markers in patients with CKD. Assessment of renal function is important for the interpretation of OPN levels in patients with atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486990     DOI: 10.1111/j.1365-2362.2010.02271.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  20 in total

1.  Relationship of osteopontin and renal function with severity of coronary artery lesions.

Authors:  Jian Chen; Yingmin Lu; Damin Huang; Xiaohan Luo; Yachen Zhang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Urinary Osteopontin Predicts Incident Chronic Kidney Disease, while Plasma Osteopontin Predicts Cardiovascular Death in Elderly Men.

Authors:  Tobias Feldreich; Axel C Carlsson; Johanna Helmersson-Karlqvist; Ulf Risérus; Anders Larsson; Lars Lind; Johan Ärnlöv
Journal:  Cardiorenal Med       Date:  2017-05-25       Impact factor: 2.041

3.  Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification.

Authors:  Neil J Paloian; Elizabeth M Leaf; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2016-03-09       Impact factor: 10.612

Review 4.  Immunologic and endocrine functions of adipose tissue: implications for kidney disease.

Authors:  Qingzhang Zhu; Philipp E Scherer
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

5.  [Retroperitoneal fibrosis: development of a biomarker profile for diagnosis and therapy monitoring].

Authors:  S Kukuk; A Kretschmer; H Bruck; S Roth; A S Brandt
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

6.  Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients.

Authors:  Marco Quaglia; Annalisa Chiocchetti; Tiziana Cena; Claudio Musetti; Sara Monti; Nausicaa Clemente; Umberto Dianzani; Corrado Magnani; Piero Stratta
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980

7.  Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.

Authors:  Sandra Geschka; Axel Kretschmer; Yuliya Sharkovska; Oleg V Evgenov; Bettina Lawrenz; Andreas Hucke; Berthold Hocher; Johannes-Peter Stasch
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

8.  Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.

Authors:  Johan M Lorenzen; Celina Schauerte; Anika Hübner; Malte Kölling; Filippo Martino; Kristian Scherf; Sandor Batkai; Karina Zimmer; Ariana Foinquinos; Tamas Kaucsar; Jan Fiedler; Regalla Kumarswamy; Claudia Bang; Dorothee Hartmann; Shashi K Gupta; Jan Kielstein; Andreas Jungmann; Hugo A Katus; Frank Weidemann; Oliver J Müller; Hermann Haller; Thomas Thum
Journal:  Eur Heart J       Date:  2015-04-21       Impact factor: 29.983

9.  Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease.

Authors:  Sabrina H Rossi; Emily P McQuarrie; William H Miller; Ruth M Mackenzie; Jane A Dymott; María U Moreno; Chiara Taurino; Ashley M Miller; Ulf Neisius; Geoffrey A Berg; Zivile Valuckiene; Jonathan A Hannay; Anna F Dominiczak; Christian Delles
Journal:  BMC Nephrol       Date:  2013-08-13       Impact factor: 2.388

10.  Fetuin, matrix-Gla protein and osteopontin in calcification of renal allografts.

Authors:  Johan M Lorenzen; Filippo Martino; Irina Scheffner; Verena Bröcker; Holger Leitolf; Hermann Haller; Wilfried Gwinner
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.